Come-back kid Dendreon makes key appointments

Dendreon Pharmaceuticals, a commercial-stage biopharmaceutical company and pioneer in the development of immunotherapy treatments that are changing cancer care, has announced several key leadership appointments to further the company’s continued growth and expansion.

Re-established as an independent company after a remarkable turnaround, Dendreon has grown significantly – adding more than 60 new employees across its three US locations.

In June this year, Valeant Pharmaceuticals International (NYSE: VRX) completed the sale of all of the outstanding equity interests in its former subsidiary Dendreon Pharmaceuticals LLC to the Sanpower Group, a private Chinese conglomerate, for $819.9 million in cash.